Andreas F. Hottinger

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2017 · 2.6K citations · Full text

Medicine, Neurosurgery, Oncology +16

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · JAMA · 2015 · 1.2K citations · Full text

Medicine, Oncology, Radiation Oncology +15

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal et al. · New England Journal of Medicine · 2023 · 719 citations · Full text

Medicine, Neurology, Oncology +8

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Roger Stupp, Sophie Taillibert, Andrew A. Kanner et al. · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · 2017 · 641 citations

Medicine, Neurosurgery, Oncology +16